Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkins lymphomas (NHL) and certain autoimmune diseases[1].
Molekulargewicht:
(146.58 kDa)
Reinheit:
99.53
CAS Nummer:
[205923-57-5]
Target-Kategorie:
CD22
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten